AstraZeneca – Patient Worthy

FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients

Post author:Bree Clare
Post published:November 24, 2025
Post category:Hypereosinophilic syndrome

Hypereosinophilic syndrome (HES) patients may finally have a meaningful treatment option. According to an article published at BusinessWire.com, AstraZeneca's FASENRA (benralizumab) has shown statistically significant efficacy in delaying disease progression,…

FDA Responds to AstraZeneca’s sBLA for Chronic Rhinosinusitis Drug

Post author:Kendall Mason
Post published:March 17, 2022
Post category:nasal polyposis Rare Disease

AstraZeneca has previously submitted a supplemental Biologics License Application (sBLA) for their chronic rhinosinusitis with nasal polyps (CRwNP) treatment, and now, the FDA has responded. In a complete response letter…

source: pixabay.com

Intranasal COVID-19 Vaccine Reduces Viral Shedding

Post author:Jessica Lynn
Post published:August 2, 2021
Post category:COVID-19

As of today, the world has been battling the COVID-19 pandemic for over 1.5 years. Throughout the world, the novel coronavirus is responsible for 197 million cases and approximately 4.7…

ulleo / Pixabay

COVID-19 Vaccine Trial Resumes in the US

Post author:Kendall Mason
Post published:November 9, 2020
Post category:COVID-19 Transverse myelitis

Currently, there are a number of vaccines for COVID-19 that are being investigated, one of which is AZD1222. The trial was paused back in September when a participant became ill…

FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients

FDA Responds to AstraZeneca’s sBLA for Chronic Rhinosinusitis Drug

Intranasal COVID-19 Vaccine Reduces Viral Shedding

COVID-19 Vaccine Trial Resumes in the US

Let’s Work Together!

Keep Up to Date

Learn More